Genmab A/S

DKK 2,025.00-DKK 12.00 (0.59%)

Estimate

P/E

24.7

EPS

81.84

Beta

0.685

Growth

Revenue, YoY

676.79%

Net income, YoY

75.76%

FCF, YoY

-104.95%

Forecast

P/E (FWD)

EPS (FWD)

106.818

About the company

Ticker

GMAB

ISIN

DK0010272202

Country

Denmark

Sector (GICS)

Healthcare

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Frequently asked questions

What sector does Genmab A/S (GMAB) operate in?

Genmab A/S belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Genmab A/S (GMAB) current stock price?

As of the latest data, Genmab A/S stock price is DKK 2,025.00, with a previous close of DKK 2,037.00. Genmab A/S lost -DKK 12.00 in the last trading session, representing a -0.59% loss.

What is Genmab A/S (GMAB) current market capitalization?

Genmab A/S market cap is approximately 126.27 billion.

What is Genmab A/S (GMAB) Earnings Per Share (EPS)?

The trailing EPS is DKK 81.84, and the forward EPS is DKK 106.82.

What is Genmab A/S (GMAB) Price-to-Earnings (P/E) ratio?

Genmab A/S current P/E ratio is 24.74, with a forward P/E of 18.96.

What is Genmab A/S (GMAB) EBITDA?

Genmab A/S EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 1.39 billion.

Does Genmab A/S (GMAB) pay dividends?

No. Genmab A/S does not pay a dividend.

How did Genmab A/S (GMAB) perform in its most recent earnings report?

In the last report (June 30, 2026), Genmab A/S posted an EPS surprise of 3.79% and a revenue surprise of 2.31%.

What is Genmab A/S (GMAB) beta (volatility) score?

Genmab A/S has a beta of 0.685, indicating lower volatility than the overall market.